These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19789315)

  • 21. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.
    King GD; Muhammad AK; Xiong W; Kroeger KM; Puntel M; Larocque D; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2008 May; 82(9):4680-4. PubMed ID: 18287240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
    VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
    Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.
    VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG
    Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.
    Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG
    Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bystander killing effect of tymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells.
    Mori K; Iwata J; Miyazaki M; Osada H; Tange Y; Yamamoto T; Aiko Y; Tamura M; Shiroishi T
    Neurol Med Chir (Tokyo); 2010; 50(7):545-53. PubMed ID: 20671379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.
    Lowenstein PR; Castro MG
    Adv Pharmacol; 2016; 76():147-73. PubMed ID: 27288077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for brain tumors: basic developments and clinical implementation.
    Assi H; Candolfi M; Baker G; Mineharu Y; Lowenstein PR; Castro MG
    Neurosci Lett; 2012 Oct; 527(2):71-7. PubMed ID: 22906921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells.
    Glaser T; Castro MG; Löwenstein PR; Weller M
    Gene Ther; 2001 Mar; 8(6):469-76. PubMed ID: 11313826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AG; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-690. PubMed ID: 28178463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
    Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
    Faisal SM; Castro MG; Lowenstein PR
    Mol Ther; 2023 Oct; 31(10):2839-2860. PubMed ID: 37574780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FasL gene knock-down therapy enhances the antiglioma immune response.
    Jansen T; Tyler B; Mankowski JL; Recinos VR; Pradilla G; Legnani F; Laterra J; Olivi A
    Neuro Oncol; 2010 May; 12(5):482-9. PubMed ID: 20406899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.
    Puntel M; A K M GM; Farrokhi C; Vanderveen N; Paran C; Appelhans A; Kroeger KM; Salem A; Lacayo L; Pechnick RN; Kelson KR; Kaur S; Kennedy S; Palmer D; Ng P; Liu C; Krasinkiewicz J; Lowenstein PR; Castro MG
    Toxicol Appl Pharmacol; 2013 May; 268(3):318-30. PubMed ID: 23403069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
    Chang JW; Lee H; Kim E; Lee Y; Chung SS; Kim JH
    Neurosurgery; 2000 Oct; 47(4):931-8; discussion 938-9. PubMed ID: 11014433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma.
    Miletic H; Fischer YH; Giroglou T; Rueger MA; Winkeler A; Li H; Himmelreich U; Stenzel W; Jacobs AH; von Laer D
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6761-8. PubMed ID: 18006778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
    Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
    Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited efficacy of gene transfer in herpes simplex virus-thymidine kinase/ganciclovir gene therapy for brain tumors.
    Hadaczek P; Mirek H; Berger MS; Bankiewicz K
    J Neurosurg; 2005 Feb; 102(2):328-35. PubMed ID: 15739562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.